Filipa Mendes

Has grant

Universidade de Aveiro
Country flagPortugal

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Ruthenium-peptide conjugates: arrows for selectively targeting breast cancer

Open Date: 2021-03-01

Close Date:

Grant: Close

Organelle-targeted Radiocomplexes for Auger Therapy of Cancer

Open Date: 2021-01-01

Close Date: 2023-12-01

Grant: Close

In-beam Time-of-Flight (TOF) Positron Emission Tomography (PET) for proton radiation therapy

Open Date: 2020-01-01

Close Date:

Grant: Close

Targeting the transporters of cationic amino acids for cancer radiotheranostics: experimental and computational chemistry approach

Open Date: 2018-09-01

Close Date:

Grant: Close

Novel Molecular Imaging tools for Cystic Fibrosis

Open Date: 2018-08-01

Close Date:

Articles (10)

Year:

2023

Despite being standard tools in research, the application of cellular and animal models in drug development is hindered by several limitations, such as limited translational significance, animal ethics, and inter-species physiological differences. In this regard, 3D cellular models can be presented as a step forward in biomedical research, allowing for mimicking tissue complexity more accurately than traditional 2D models, while also contributing to reducing the use of animal models. In cancer research, 3D models have the potential to replicate the tumor microenvironment, which is a key modulator of cancer cell behavior and drug response. These features make cancer 3D models prime tools for the preclinical study of anti-tumoral drugs, especially considering that there is still a need to develop effective anti-cancer drugs with high selectivity, minimal toxicity, and reduced side effects. Metallodrugs, especially transition-metal-based complexes, have been extensively studied for their therapeutic potential in cancer therapy due to their distinctive properties; however, despite the benefits of 3D models, their application in metallodrug testing is currently limited. Thus, this article reviews some of the most common types of 3D models in cancer research, as well as the application of 3D models in metallodrug preclinical studies.

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (14)

António Paulo

-

PORTUGAL
View details

Federico Herrera

Auxiliary professor

Universidade de Aveiro

PORTUGAL
View details

Catarina Reis

Assistant Professor

University of Lisbon

PORTUGAL
View details

Isabel Correia

Auxiliary Professor

Instituto Superior Técnico

PORTUGAL
View details

Ana Belchior

professor Auxiliar Convidado

Universidade de Lisboa Instituto Superior Técnico

PORTUGAL
View details

João Carlos Waerenborgh

Universidade de Lisboa Instituto Superior Técnico

PORTUGAL
View details

Tânia S. Morais

Universidade de Aveiro

PORTUGAL
View details

Maria Manuela Gaspar

Universidade de Aveiro

PORTUGAL
View details

Daniel Galaviz Redondo

Assistant Professor

Faculdade de Ciências da Universidade de Lisboa

PORTUGAL
View details

Lurdes Gano

Researcher

Universidade de Lisboa Instituto Superior Técnico

PORTUGAL
View details

Célia Fernandes

Universidade de Aveiro

PORTUGAL
View details

Laura C. J. Pereira

Universidade de Aveiro

PORTUGAL
View details

Simonetta Geninatti Crich

Associate professor

University of Turin

ITALY
View details

Gonçalo Bernardes

Professor of Chemical Biology

University of Cambridge Department of Medicine

UNITED KINGDOM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.